Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment
Open Access
- 1 December 2001
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research
- Vol. 3 (6) , 395-398
- https://doi.org/10.1186/bcr329
Abstract
Overexpression of the ERBB2 proto-oncogene is associated with amplification of the gene in breast cancer but increased activity of the promoter also plays a significant role. Members of two transcription factor families (AP-2 and Ets) show increased binding to the promoter in over-expressing cells. Consequently, strategies have been devised to target promoter activity, either through the DNA binding sites for these factors, or through another promoter sequence, a polypurine-polypyrimidine repeat structure. The promoter has also been exploited for its tumour-specific activity to direct the accumulation of cytotoxic compounds selectively within cancer cells. Our current understanding of the ERBB2 promoter is reviewed and the status of these therapeutic avenues is discussed.Keywords
This publication has 29 references indexed in Scilit:
- Ets regulation of the erbB2 promoterOncogene, 2000
- Overexpression of ErbB2 in cancer and ErbB2-targeting strategiesOncogene, 2000
- Targeting the Ets Binding Site of the HER2/neuPromoter with Pyrrole-Imidazole PolyamidesJournal of Biological Chemistry, 2000
- Insulation of a conditionally expressed transgene in an adenoviral vectorGene Therapy, 1999
- Identification of a Novel Promoter and Exons of the c-ERBB-2GeneBiochemical and Biophysical Research Communications, 1999
- Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectorsCancer Gene Therapy, 1999
- Inhibition of Gene Expression from the Human c-erbB Gene Promoter by a Retroviral Vector Expressing Anti-gene RNABiochemical and Biophysical Research Communications, 1997
- Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzymeGene Therapy, 1997
- HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancerOncogene, 1997
- An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expressionOncogene, 1997